February 19/PRNewswire/ -- Ferring Pharmaceuticals announced today that it has received marketing authorisation from the European Commission, for FIRMAGON (degarelix), a new GnRH receptor antagonist indicated for patients with advanced, hormone-dependent prostate cancer.
The details can be read here.
No comments:
Post a Comment